Aktie im Blick: Anleger misstrauen den Zukunftsplänen von Novo Nordisk
Der Hersteller von Abnehmspritzen und Weltmarktführer für Insulinprodukte blickt weit in die Zukunft. Doch das reicht Anlegern nicht. Ein großer Wettbewerber macht es besser.
Düsseldorf - The Danish pharmaceutical company Novo Nordisk dominated digital stock forums last week, sparking a flurry of debate. The catalyst was its highly anticipated capital market day in London on the previous Monday, where the company projected plans to launch over five blockbuster drugs by 2030, generating over 20 billion euros in revenue.
Additionally, Novo Nordisk expects the innovative weight loss medication Cagri-Sema to outperform existing drugs, with greater weight loss results. The US approval decision for Cagri-Sema is expected in the fourth quarter of this year.
While these ambitions garnered significant attention, the stock price fell by roughly ten percent over the past week. Investors were seeking more detailed financial forecasts and sales projections, rather than simply lofty ambitions. Several analyst houses, including Jefferies and Deutsche Bank, subsequently lowered their price targets.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Stock in focus: Investors distrust Novo Nordisk's future plans handelsblatt.com
